| Description | Fremanezumab (TEV-48125), a humanized IgG2a monoclonal antibody, potently and selectively targets the calcitonin gene-related peptide (CGRP), a 37-amino acid neuropeptide implicated in the central and peripheral mechanisms of migraine. It holds promise for research into chronic migraine treatment [1]. |
| molecular weight | N/A |
| CAS | 1655501-53-3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 years |